In a significant development in the fight against dengue fever, the World Health Organization (WHO) has granted prequalification to Takeda's new dengue vaccine. This endorsement marks a crucial step forward in combatting the disease, which affects millions of people worldwide annually.

The decision by the WHO follows rigorous evaluation of Takeda's vaccine, which has shown promising results in clinical trials. Dengue fever, a mosquito-borne viral infection, poses a significant public health threat, particularly in tropical and subtropical regions. The lack of a widely available vaccine has hindered efforts to control the spread of the disease.

With WHO prequalification, Takeda's dengue vaccine can now be procured by United Nations agencies and other global health organizations, paving the way for expanded access to populations at risk. This milestone underscores the importance of continued investment in research and development to address infectious diseases and improve global health outcomes.

Takeda's commitment to combating dengue fever extends beyond vaccine development. The company has also been involved in community engagement initiatives and public health campaigns to raise awareness about dengue prevention and control measures.

The prequalification of Takeda's dengue vaccine represents a significant achievement in the ongoing efforts to tackle dengue fever and reduce its burden on affected communities worldwide.